Daniel O’Mahony is a Partner at the pan European life sciences VC Seroba Kernel Life Sciences, investing in companies developing new medical devices or therapeutics. Daniel O’Mahony brings a wealth of experience in product development, strategic planning, licensing, intellectual property management and commercialisation across the Medtech, pharma and biotech industry sectors and in venture capital and corporate investments. He previously worked in Elan Corporation plc and Taro Pharmaceuticals Inc.
In 2005 he established the Technology Transfer Office at NUI, Galway. Daniel O’Mahony graduated with a PhD from the National University of Ireland, Cork and holds a business degree in technology management from the Smurfit Business School, University College Dublin.
He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA and the Department of Medicine & Experimental Therapeutics at University College Dublin. He was published in several scientific journals, is co-inventor on numerous patent families and is a regular panel member at major international Medtech conferences. He is a former member of the Irish government’s Innovation Task Force intellectual property strategy sub-group. Daniel O’Mahony currently sits on the Boards of Novate Medical and PQ Bypass Irl. Ltd. He also sat on the Boards of Apica Cardiovascular, Covagen and Stokes Bio prior to their acquisitions by Thoratec (July 2014), Cilag / Janssen Pharmaceutical companies of the Johnson & Johnson Group (August 2014) and Life Technologies, respectively.